Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

BACKGROUND: To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs. METHODS: Patients in SELECT-NEXT, a randomised controlled trial, were on a background of csDMARDs and received upadacitinib 15 mg and 30 mg or placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902348/
https://www.ncbi.nlm.nih.gov/pubmed/31815649
http://dx.doi.org/10.1186/s13075-019-2037-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902348/
https://www.ncbi.nlm.nih.gov/pubmed/31815649
http://dx.doi.org/10.1186/s13075-019-2037-1

Ejemplares similares